Reclassification Under the Controlled Substances Act (CSA) Offers a New Pathway for Institutions and US Investment Banking to Participate in the Cannabis Industry
‘On
Ultimately, the DEA has final authority with respect to rescheduling and will consider factors such as the history of abuse (e.g., scope, duration, patterns, etc.), the relative potential for abuse, and the risk to public health. DEA will also consider any scientific evidence (e.g., pharmacological effect, physiological dependence, etc.) regarding marijuana/cannabis.
This marks the first significant policy shift regarding Marijuana/Cannabis by the FDA since Cannabis was made illegal.
Pathway to Potential Benefits for the Cannabis Industry if Reclassified:
- Safer banking and management of cash
- Regulatory compliance simplification
- US Based Public company participation
- US Based Investment Banking and Capital Formation
- US Leadership in
International Trade - Physician Participation with Patients
- Institution and
Academic Research
The Farm Bill of 2018 concerning Hemp legalization expires this Fall and must be extended and/or modified. The reclassification of Marijuana/Cannabis under the Controlled Substances Act (CSA) would coincide nicely with any modifications needed with the new Farm Bill to be drafted for 2023. Simply stated, this potential policy and reclassification movement is good for the US economy and will provide thousands of jobs and significant deployment of capital needed to fund research, regulatory compliance and capital formation in the US.
In
www.endexx.com & www.cbdunlimited.com
www.tryhyla.com
About
Hyla currently markets its proprietary non-nicotine, guarana and L-Dopa-based vape products in a wide variety of flavors. The Hyla device is the first non-nicotine vape product to be produced in this manner in
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the
No Offer or Solicitation. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and, where applicable, the requirements under the securities laws of any other applicable jurisdiction.
For further information, please contact:
IR@Endexx.com
480-595-6900
![](https://ml.globenewswire.com/media/NGM5YjUwNzAtODVlNC00ODQzLWJkMzctZDU5ZmUwNjk0ZjNlLTUwMDAzMjE5OA==/tiny/Endexx-Corporation.png)
2023 GlobeNewswire, Inc., source